Ishikawa Dai, Zhang Xiaochen, Nagahara Akihito
Juntendo Med J. 2025 Mar 12;71(2):68-75. doi: 10.14789/ejmj.JMJ24-0045-R. eCollection 2025.
In recent years, the impact of gut microbiota on human health has gained increasing recognition, highlighting the potential benefits of regulating gut microbiota for patient care. Consequently, fecal microbiota transplantation (FMT) has emerged as a novel treatment for improving dysbiosis. It is necessary to summarize and discuss the current research and future development possibilities. This advanced microbial therapy restores the gut microbiome by introducing a diverse array of microorganisms from healthy donors, thereby correcting dysbiosis and re-establishing a fully functional ecosystem. Ongoing research on FMT is actively conducted in various fields worldwide. This study provides an overview of the progress of clinical research on the effects of FMT in gastrointestinal diseases, immune checkpoint inhibitors, allergic diseases, and central nervous system diseases, as well as the results of our ongoing clinical study on "FMT combined with antibiotics for ulcerative colitis."
近年来,肠道微生物群对人类健康的影响日益受到认可,这凸显了调节肠道微生物群对患者护理的潜在益处。因此,粪便微生物群移植(FMT)已成为一种改善菌群失调的新型治疗方法。有必要总结和讨论当前的研究以及未来的发展可能性。这种先进的微生物疗法通过引入来自健康供体的多种微生物来恢复肠道微生物组,从而纠正菌群失调并重新建立一个功能齐全的生态系统。全球各地的各个领域都在积极开展关于FMT的研究。本研究概述了FMT在胃肠道疾病、免疫检查点抑制剂、过敏性疾病和中枢神经系统疾病方面临床研究的进展,以及我们正在进行的“FMT联合抗生素治疗溃疡性结肠炎”临床研究的结果。